Preliminary Screening of Crude Extracts of Fagaropsis Angolensis for Anticancer Activity

groupview

Abstract
Pharmacognosy Communications,2018,8,2,xx-xx.
Published:April 2018
Type:Original Article

Preliminary Screening of Crude Extracts of Fagaropsis Angolensis for Anticancer Activity

Antony Letoyah Yiaile1,2*, James Mucunu Mbaria2, Isaac Mpapuluu Ole-Mapenay2, Mitchel Otieno Okumu2, Abdi Hussein Hadun2, Jared Misonge Onyancha3

1Department of Pharmacy, University Health Services, Maasai Mara University, P.O. Box 861-20500, Narok, KENYA.

2Department of Public Health, Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Nairobi, P.O. Box 29053-00625, Nairobi, KENYA.

3Department of Pharmacy, School of Medicine and Health Sciences, Kenya Methodist University, P.O BOX 267-60200 Meru, KENYA.

Abstract:

Background: The use of conventional cancer medication is limited by cytotoxicity on normal cells, intolerability of the drugs used and emergence of aggressive tumors which do not respond to treatment. Herbal alternatives are now being touted to be of promising efficacy. Fagaropsis angolensis (FA) has wide ranging ethno medicinal uses in Kenya. However, the anticancer potential of this plant is yet to be fully explored. The present study aims to determine the antiproliferative activity of crude extracts of Fagaropsis angolensis (FA) against African monkey kidney (Vero, E6), throat cancer (Hep2) and colon cancer (CT 26-CL 25) cell lines. Methods: Water and methanol extracts of FA were qualitatively screened to determine their phytochemical composition. In vitro growth inhibition capacity of these extracts on African monkey kidney (Vero, E6), throat cancer (HeP2) and colon cancer (CT-26-CL-25) cell lines was then assessed using the 3-(4, 5-dimethylthiazol- 2-yl)-2, 5-diphenyltetrazolium assay and expressed as 50% inhibitory concentration (IC50). Doxorubicin (standard anticancer agent) was used for comparison. Results: On Vero cell lines, statistical differences (p<0.05) were noted in the IC50 values of methanol whole root and methanol root stem extracts of FA (5.80+/-0.80μg/ml) against 1.10+/-0.70μg/ml) as well as between Doxorubicin and methanol root stem extracts of FA (6.5+/-3.25 μg/ml against 1.10+/-0.70μg/ml). On colon cancer cell lines, statistical differences (p<0.05) were noted between the IC50 values of Doxorubicin and the methanol root stem extract of FA (19.00+/-9.00ug/ml against 8.33+/-1.42μg/ml) as well as between Doxorubicin and methanol whole root extract of FA (19.00+/-9.00μg/ml against 5.25+/-0.35μg/ml). The effects of the extracts of FA on throat cancer cell lines were unremarkable. Conclusions: These findings suggest that the choice of solvent may have some effect on the IC50 values of the extracts on cancer cell lines. It may also be suggested that the methanol root stem and whole root extracts of FA may be sources of important lead molecules that may be useful in the treatment of colon cancer. Conclusion: These findings suggest that the methanol root stem and whole root extracts of FA may be sources of important lead molecules in cancer therapy.

Founded:  In 2004, as the PHCOG.NET – a non-profit private organization dedicated to Natural Products Research leading to develop promising drugs. Our main mission is to make information on herbal drug research readily available in different formats to suit the individual needs.

Pharmacognosy Communications [Phcog Commn.] is a new quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the  publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.

The journal aims to cater the latest outstanding developments in the field of pharmacognosy and natural products and drug design covering but not limited to the following topics:

  • Pharmacognosy and pharmacognistic investigations
  • Research based ethnopharmacological evaluations
  • Biological evaluation of crude extracts, essential oils and pure isolates
  • Natural product discovery and evaluation
  • Mechanistic studies
  • Method and technique development and evaluation
  • Isolation, identification and structural elucidation of natural products
  • Synthesis and transformation studies

Distinctions:  The most widely read, cited, and known Pharmacognosy Communications and website is well browsed with all the articles published. More than 20,000 readers in nearly every country in the world each month

Aim and Scope | Editorial Board | Indexed & Abstracted | Instruction to Authors | Manuscript Submission & Charges

Subjects Covered : Natural Products, Pharmacognosy, Phytochemistry, Marine Pharmacognosy and Zoo Pharmacognosy
ISSN :2249-0159 (Print) ; 2249-0167 (Online) Frequency : Quarterly Rapid at a time publication (4 issues/year)

Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online  publication is 45 days.
Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.